Oncolinx

Oncolinx is engaged in the development of advanced targeted cancer therapies known as antibody-drug conjugates (ADCs), in collaboration with the National Cancer Institute. These ADCs utilize a patented immune-activating drug payload called Azonafide, which is specifically designed to target cancer cells while sparing healthy cells, thus minimizing the side effects commonly associated with traditional chemotherapy. The company is partnered with over 14 leading pharmaceutical companies and 6 academic laboratories worldwide, working on ADCs for 30 different cancer indications. This innovative approach not only aims to induce cancer cell death but also to stimulate the immune system, offering a potentially less painful alternative to conventional treatments. Oncolinx plans to initiate clinical trials for one of its partnered programs.